<DOC>
	<DOCNO>NCT00001521</DOCNO>
	<brief_summary>This study develop determine combination four drug ( flutamide , testolactone , reduce hydrocortisone dose , fludrocortisone ) normalize growth child congenital adrenal hyperplasia . The study take 60 child , boys girl divide 2 group base medication give . Group one receive new four- drug combination . Group two receive standard treatment congenital adrenal hyperplasia ( hydrocortisone fludrocortisone ) . The boy group one take medication age 14 time stop take four drug combination begin receive standard treatment congenital adrenal hyperplasia . Girls group one take four drug combination age 13 , time stop begin receive standard treatment congenital adrenal hyperplasia plus flutamide . Flutamide give girl six month first menstrual period . All child follow reach final adult height . The effectiveness treatment determine measure patient 's adult height , body mass index , bone density . &lt; TAB &gt;</brief_summary>
	<brief_title>Three Drug Combination Therapy Versus Conventional Treatment Children With Congenital Adrenal Hyperplasia</brief_title>
	<detailed_description>To test hypothesis regimen flutamide ( antiandrogen ) , testolactone letrozole ( inhibitor androgen-to-estrogen conversion ) , reduce hydrocortisone dose normalize growth adult stature child congenital adrenal hyperplasia , avoid complication supraphysiologic glucocorticoid dosage , 60 child disorder randomize receive either regimen conventional treatment reach age 13 year girl age 14 boy . After age boys receive conventional treatment girl receive conventional treatment plus flutamide . In girl , flutamide continue 6 month menarche . All child follow attained final adult height . The principal outcome measure adult height , body mass index , bone density .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Adrenal Hyperplasia , Congenital</mesh_term>
	<mesh_term>Adrenogenital Syndrome</mesh_term>
	<mesh_term>Adrenocortical Hyperfunction</mesh_term>
	<mesh_term>Growth Disorders</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<mesh_term>Testolactone</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<criteria>INCLUSION CRITERIA : Subjects boys bone age 2 13 year girls bone age 2 11 year classic 21hydroxylase . Subjects must either yet undergone pubertal activation hypothalamicpituitarygonadal axis , , pubertal activation occur , must receive LHRH agonist suppress secondary central precocious puberty . Children bone age 1 2 year may enroll protocol optimization conventional therapy , randomize study arm bone age reach 2 . EXCLUSION CRITERIA : Children concurrent illnesses require glucocorticoid treatment ( severe asthma ) , require drug markedly alter hydrocortisone metabolism ( anticonvulsant ) , child bring reasonable control conventional treatment ( unusual occurrence ) .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>January 11, 2017</verification_date>
	<keyword>21-Hydroxylase Deficiency</keyword>
	<keyword>11-Hydroxylase Deficiency</keyword>
	<keyword>Antiandrogen</keyword>
	<keyword>Aromatase Inhibitor</keyword>
	<keyword>Growth Disorder</keyword>
	<keyword>Congenital Adrenal Hyperplasia ( CAH )</keyword>
</DOC>